FAQs

Luna Therapeutics is a life science company founded to supply microcarriers and 3D biomaterials for research, bioprocessing and regenerative medicine. The company started operations in 2021, following a decade of laboratory and clinical R&D by teams at University College London led by Richard Day.

CytoStrat® is a versatile implantable microcarrier technology designed for advanced bioprocessing applications. It enables tunable cell attachment, viability, and scalability for implantable therapies like regenerative medicine, drug delivery, and tissue engineering.

Unlike traditional microcarriers, CytoStrat® is implantable and customizable. Its tunable properties – such as surface chemistry, porosity, stiffness, and degradation rate – support optimal cell attachment and natural anchoring, making it ideal for delivery of advanced cell-based therapies.

CytoStrat® is designed for biopharma companies, researchers, and manufacturers involved in cell therapy, bioprocessing, and regenerative medicine.

CytoStrat® supports many anchorage dependent cell types, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), epithelial cells, and myoblasts.

CytoStrat® features advanced surface topography, porosity, and stiffness, mimicking natural cell environments to promote robust adhesion and growth. These features can be tailored to enhance cell behavior, such as differentiation, as well as cell yield.

Yes. CytoStrat® is compatible with most bioreactor systems and cell culture equipment, allowing seamless integration into your existing workflows.

CytoStrat® microcarriers are available in a variety of sizes, from submicron to millimeter-scale, and are offered in both non-sterile and sterile formats.

Yes, CytoStrat® is produced under GMP-compliant processes, ensuring the highest quality and safety standards for clinical use.

Yes. CytoStrat® is designed for scalability, accommodating production quantities from milligrams to kilograms to meet the needs of research, clinical trials, and commercial manufacturing.

By combining cells and microcarriers into an implantable product, CytoStrat® minimizes cell handling, reduces contamination risk, and streamlines regulatory processes.

Yes, CytoStrat® has undergone early Phase clinical testing and has shown no observed toxicity or safety concerns in humans.

CytoStrat® microcarriers are made from clinically approved, biocompatible materials, such as PLGA and other advanced polymers.